<DOC>
	<DOC>NCT02856646</DOC>
	<brief_summary>The purpose of this study is to gather data on patients diagnosed with and treated for classical Hodgkin Lymphoma (cHL). It aims to closely observe how treatment for cHL is rendered, as well as assess the outcome of those treatment options and their impact on quality of life. Additional analyses will also attempt to identify prognostic or predictive biomarkers</brief_summary>
	<brief_title>Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Histologically confirmed diagnosis of Classical Hodgkin Lymphoma (cHL) Patients who are treatmentnaïve, or are within ± 2 weeks beginning any line of therapy at time of enrollment Patients must be within ± 2 weeks of Day 1 of the first cycle of any line of therapy to enroll; a cycle is practicedefined for chemotherapy, targeted therapy, or immunotherapybased regimens. Any Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status (PS) Patients must have available medical records for the date of diagnosis of cHL and available medical records documenting any prior treatment and treatment dates for the Hodgkin lymphoma, including chemotherapy, radiation, surgery and other anticancer therapy received. Patients must consent for use of their FFPE tissue blocks for exploratory analyses Patients on supportive care only and not receiving anticancer therapy are not eligible to enroll Patients with unknown date of diagnosis of cHL Patients whose prior cHL therapy, and dates of therapy (eg, surgery, radiation, or drug therapy) are unknown Any other nonHL (nonHodgkin Lymphoma) active malignancy for which the patient is receiving treatment Patients participating in a clinical study that does not allow enrollment into a noninterventional study Patients enrolled who go on to receive only supportive, palliative, hospice, or endoflife care remain on study and should not be discontinued from followup. Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>